Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00220051
Other study ID # 1973
Secondary ID
Status Completed
Phase Phase 2
First received September 19, 2005
Last updated May 30, 2013
Start date November 2001

Study information

Verified date May 2013
Source Royal Marsden NHS Foundation Trust
Contact n/a
Is FDA regulated No
Health authority United Kingdom: Medicines and Healthcare Products Regulatory Agency
Study type Interventional

Clinical Trial Summary

To assess the efficacy and safety of pre-operative capecitabine and oxaliplatin followed by capecitabine with concurrent radiotherapy followed by post-operative capecitabine in the treatment of patients with locally advanced or inoperable rectal cancer.


Recruitment information / eligibility

Status Completed
Enrollment 109
Est. completion date
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Age over 18.

- Histological diagnosis of adenocarcinoma of rectum.

- Locally advanced/ poor prognosis primary rectal cancer defined by MRI criteria of any of the categories below;

- Tumour within 2 mm of mesorectal fascia ie circumferential resection margin threatened

- Any T3 tumour at/below levatores

- T3c tumour at any other level ie tumour extends >5 mm into peri-rectal fat

- T4 tumour

- Any T stage with 4 or more involved lymph nodes

- WHO performance status 0, 1 or 2.

- No evidence of metastatic disease as determined by CT scan of chest, abdomen, pelvis or other investigations such as PET scan or biopsy if required.

- Adequate bone marrow function with platelets > 100 X 109/l; WBC > 3 X 109/l; neutrophils > 1.5 X 109/l

- Normal renal function, with serum creatinine within the normal range or calculated creatinine clearance >50 ml/min.

- Adequate hepatic function with serum total bilirubin < 1.5 X upper limit of normal range.

- No concurrent uncontrolled medical conditions

- No previous malignant disease other than non-melanotic skin cancer or carcinoma in situ of the uterine cervix

- Adequate contraceptive precautions if relevant

- Informed written consent

Exclusion Criteria:

- Medical or psychiatric conditions that compromise the patient's ability to give informed consent

- Presence of metastatic disease or recurrent rectal tumour

- Renal impairment (creatinine clearance<30 ml/min)

- Pregnancy or breast feeding

- Patients with a lack of physical integrity of the upper gastrointestinal tract, or known malabsorption syndromes

- Participation in any investigational drug study within the previous 4 weeks.

- Clinically significant (i.e. active) cardiac disease (e.g. congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmia even if controlled with medication) or myocardial infarction within the last 12 months)

- Patients with any symptoms or history of peripheral neuropathy.

- Prior pelvic radiotherapy

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Oxaliplatin, Capecitabine

Procedure:
Pre operative radiotherapy

Surgical Resection


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Royal Marsden NHS Foundation Trust

Outcome

Type Measure Description Time frame Safety issue
Primary Pathological complete response rate.
Primary Acute toxicity has been evaluated in previous phase I studies and should occur to a similar extent.
Secondary Progression-free survival
Secondary Treatment related toxicity
Secondary Overall survival
Secondary Radiological response rate
Secondary Proportion of patients achieving pathological down staging compared with the pre-treatment MRI scan
Secondary Surgical complications
Secondary Bowel function and quality of life
See also
  Status Clinical Trial Phase
Recruiting NCT06380101 - Evaluating a Nonessential Amino Acid Restriction (NEAAR) Medical Food With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LARC) N/A
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Recruiting NCT04323722 - Impact of Bladder Depletion on Mesorectal Movements During Radiotherapy in Rectal Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04088955 - A Digimed Oncology PharmacoTherapy Registry
Active, not recruiting NCT01347697 - Collagen Implant (Biological Mesh) Versus GM Flap for Reconstruction of Pelvic Floor After ELAPE in Rectal Cancer N/A
Recruiting NCT04495088 - Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer Phase 3
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Terminated NCT01347645 - Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer Phase 1/Phase 2
Not yet recruiting NCT03520088 - PROSPECTIVE CONTROLLED AND RANDOMIZED STUDY OF THE GENITOURINARY FUNCTION AFTER RECTAL CANCER SURGERY IN RELATION TO THE DISSECTION OF THE INFERIOR MESENTERIC VESSELS N/A
Recruiting NCT05556473 - F-Tryptophan PET/CT in Human Cancers Phase 1
Recruiting NCT04749381 - The Role of TCM on ERAS of Rectal Cancer Patients Phase 2
Enrolling by invitation NCT05028192 - Mitochondria Preservation by Exercise Training: a Targeted Therapy for Cancer and Chemotherapy-induced Cachexia
Recruiting NCT03283540 - Transanal Total Mesorectal Excision for Rectal Cancer on Anal Physiology + Fecal Incontinence
Completed NCT04534309 - Behavioral Weight Loss Program for Cancer Survivors in Maryland N/A
Recruiting NCT05914766 - An Informational and Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer N/A
Recruiting NCT04852653 - A Prospective Feasibility Study Evaluating Extracellular Vesicles Obtained by Liquid Biopsy for Neoadjuvant Treatment Response Assessment in Rectal Cancer
Recruiting NCT03190941 - Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients Phase 1/Phase 2
Completed NCT02810652 - Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection N/A
Terminated NCT02933944 - Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer Phase 1